Candel Therapeutics (CADL.US), a biopharmaceutical company, rose nearly 18 per cent to $7.43 as of 23:39 Beijing time on Monday, Aug. 23. Credit Suisse gave the stock an "outperform" rating of $15, UBS a "buy" rating of $9 and Jeffery, an investment bank, with a "buy" rating of $22.
Founded in 2003, Candel Therapeutics is a phase III clinical biotechnology company that develops cancer immunotherapy aimed at improving the lives of cancer patients and their families.